Global Health Q1FY27 Revenue Jumps 26.5% Driven by Patient Volume Growth

Net Sales (Q1FY27): ₹1,304 crore
Adjusted PAT (Q1FY27): ₹157 crore

Reader Takeaway: Strong patient volume growth drives revenue; Noida turnaround is key for margin recovery.

What Just Happened

Global Health Limited reported a consolidated revenue of ₹1,304 crore for the first quarter of fiscal year 2027, an increase of 26.5% compared to the same period last year. This growth was fueled by significant increases in patient volumes, with inpatient volume rising by 28% and outpatient volume by 34%. EBITDA stood at ₹287 crore, with an EBITDA margin of 22.0%. Adjusted Profit After Tax (PAT) was ₹157 crore.

The company's Noida hospital is showing signs of operational turnaround, with its EBITDA loss narrowing to ₹5 crore from previous quarters, exceeding expectations for breakeven. However, the overall EBITDA margin remained flat year-on-year due to the ongoing ramp-up of new facilities.

Why This Matters

The strong top-line growth indicates robust demand for Global Health's services. The progress in reducing losses at the Noida facility is a critical indicator of improved operational efficiency and potential for future margin expansion. Investors are keenly watching the company's aggressive expansion plans and its ability to translate increased capacity into sustained profitability.

The Backstory

Global Health, operating under the Medanta brand, is in a phase of significant expansion. The company has been investing heavily in increasing its bed capacity and expanding its healthcare network. The Noida facility, a key part of its strategy, has been undergoing a turnaround process.

What Changes Now

The company is actively managing its expansion pipeline, including a revised plan for its Guwahati project. The project is now envisioned as a 650-bed super-specialty hospital with an increased cost of ₹970 crore and a larger floor area to accommodate enhanced procedural capacity.

Risks to Watch

Potential risks include margin pressure from the ongoing ramp-up of new hospitals, high doctor attrition rates which can affect service delivery, and the significant capital expenditure required for its expansion pipeline. The total capital expenditure program amounts to ₹4,850 crore.

Peer Comparison

While direct real-time peer data isn't provided in the filing, Global Health's growth strategy relies on increasing market share through capacity expansion, a common theme among large hospital chains in India. Key competitors focus on similar growth vectors, making execution and operational efficiency crucial differentiators.

Context Metrics (Time-Bound)

• Patient Volume Growth: Inpatient volume +28% YoY, Outpatient volume +34% YoY in Q1FY27.
• Noida Turnaround: EBITDA loss reduced to ₹5 crore in Q1FY27.
• Guwahati Project Revision: Increased to 650 beds and ₹970 crore cost.

What to Track Next

Investors should monitor the company's progress in achieving its target EBITDA margin range of 25–26% as newer facilities mature. Tracking the operational performance of the Noida hospital and the execution of the Guwahati project will be key. The overall management of the ₹4,850 crore capex program remains crucial for long-term value creation.